Medindia
Medindia LOGIN REGISTER
Advertisement

INAAT Market Size to Reach $4.3 Billion by 2025 | CAGR: 11.8%: Grand View Research, Inc.

Thursday, September 14, 2017 Research News
Advertisement
SAN FRANCISCO, September 14, 2017 /PRNewswire/ --
Advertisement

The global isothermal nucleic acid amplification technology (INAAT) market is expected to reach USD 4.3 billion by 2025, growing at a CAGR of 11.8%, according to a new report by Grand View Research, Inc. This can be attributed to significant rise in awareness regarding need for rapid and on-time testing for chronic and infectious diseases. Global increase in adoption of INAAT for detection of HIV, hepatitis A & B, and sexually transmitted diseases is considered to be a high impact rendering driver for growth.
Advertisement

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Loop-Mediated Isothermal Amplification is one of the most preferred nucleic acid amplification methods because of its ability to provide point of care testing, thus leading to increased adoption. The recently-introduced Nicking Enzyme Amplification Reaction (NEAR) and Helicase-dependent amplification (HDA) technologies are expected to experience exponential growth during the forecast period owing to their patent protection.

In addition, owing to recent epidemics of infectious diseases, such as tuberculosis, Zika virus, and influenza, importance of point of care diagnosis has increased especially in developing countries. This is also anticipated to boost demand for this technology in these regions.

Browse full research report with TOC on "Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis By Product, By Technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR, TMA, RCA, RPA, SMAP2), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/isothermal-nucleic-acid-amplification-technology-inaat-market

Further key findings from the report suggest: 

  • Reagents are expected to be fastest growing products owing to their high usage in all INAAT procedures
  • TMA was identified as the largest technology segment by revenue share in 2016 owing to its high adoption
  • Infectious disease diagnostics is expected to be the fastest growing application owing to development of numerous assays for detection of specific infectious diseases
  • Hospitals dominated the end user segment in 2016 with the largest share and are expected to be continue dominance over the forecast period owing to the high usage of INAAT in hospitals globally
  • North America held the largest share of the global market in 2016, and the U.S. held the largest revenue share in the region owing to rise in infectious diseases, availability of government funds, prevalence of cancer, application of MDx in cancer screening & genetic disorders, and self-monitoring techniques
  • The molecular diagnostics industry in Asia Pacific is projected to witness substantial growth over the next decade due to various developments in major economies, especially in the NASBA, NEAR, and HDA technology segments
  • Some of the key players in the INAAT market include Alere; bioMerieux SA; Eiken Chemical Co. Ltd.; Hologic, Inc. (Gen-Probe); Lucigen; QIAGEN; Quidel Corporation; ThermoFisher Scientific; and Becton, Dickinson & Company
  • Major players have been engaging in numerous strategic initiatives such as mergers and acquisitions to increase global presence and improve market share.
Browse related reports by Grand View Research: 

  • Cancer Pain Market - http://www.grandviewresearch.com/industry-analysis/cancer-pain-market
  • Genetic Disease Diagnostic Market - http://www.grandviewresearch.com/industry-analysis/genetic-disease-diagnostic-market
  • Diabetes Treatment Market - http://www.grandviewresearch.com/industry-analysis/diabetes-treatment-market
  • Asthma & COPD Market - http://www.grandviewresearch.com/industry-analysis/asthma-and-copd-market
Grand View Research has segmented the global INAAT market on the basis of product, technology, application, end-use, and region: 

  • Isothermal Nucleic Acid Amplification By Product Outlook (Revenue, USD Million, 2014 - 2025) 
    • Instrument
    • Reagent
  • Isothermal Nucleic Acid Amplification By Technology Outlook (Revenue, USD Million, 2014 - 2025) 
    • NASBA
    • HDA
    • LAMP
    • SDA
    • SPIA
    • NEAR
    • TMA
    • RCA
    • RPA
    • SMAP2
    • Others
  • Isothermal Nucleic Acid Amplification By Application Outlook (Revenue, USD Million, 2014 - 2025) 
    • Blood screening
    • Infectious disease diagnostics
    • Cancer
    • Others
  • Isothermal Nucleic Acid Amplification By End Use Outlook (Revenue, USD Million, 2014 - 2025) 
    • Hospitals,
    • Central and reference labs
    • Others
  • Regional Outlook (Revenue, USD Million, 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • China
      • India
      • Japan
    • Central & South America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
Read Our Blog By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected]

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.

Sponsored Post and Backlink Submission


Latest Press Release on Research News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close